The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure ...

The choline chloride market is projected to grow from USD 617.60 million in 2025 to USD 671.75 million by 2026, and reach USD 1.05 billion by 2032, at a CAGR of 7.88%. This robust trajectory is driven ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are choline deficient, which ...

(RTTNews) - Protara Therapeutics, Inc. (TARA) announced Friday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on a registrational path forward for intravenous (IV) ...

(RTTNews) - Protara Therapeutics, Inc. (TARA) has dosed the first patient in its pivotal Phase 3 registrational THRIVE-3 trial evaluating intravenous (IV) Choline Chloride in patients dependent on ...

Details concerning the Choline Chloride combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids ...

NEW YORK--(BUSINESS WIRE)--ArTara Therapeutics, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it has successfully completed an End ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...